SCHEMBL3608699

SCHEMBL3608699

N=C(N)Nc1nc(-c2ccc(OCc3ccccc3)c(N)c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
ATP4A P20648 6/20 0.47
ATP4B P51164 6/20 0.47
ENPP2 Q13822 1/20 0.44
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ELOVL1 Q9BW60 1/20 0.43
CYP3A4 P08684 1/20 0.43
PRKACA P17612 1/20 0.43
ROCK1 Q13464 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
PLAU P00749 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598965 0.84 MEN1 (0.49) MEN1KMT2AATP4AATP4BENPP2
SCHEMBL3604738 0.81 MEN1 (0.61) MEN1KMT2AALDH1A1ALOX15MAPK1
SCHEMBL3613607 0.77 LTA4H (0.59) MEN1KMT2AATP4AATP4BALDH1A1
SCHEMBL27768248 0.77 ATP4A (0.56) MEN1KMT2AATP4AATP4BELOVL1
SCHEMBL3598628 0.75 MAPT (0.58) MEN1KMT2AALDH1A1ALOX15MAPK1
SCHEMBL27768262 0.75 ABL1 (0.43) MEN1KMT2AATP4AATP4BALDH1A1
SCHEMBL3603436 0.75 MEN1 (0.61) MEN1KMT2AALDH1A1ALOX15MAPK1
SCHEMBL3607108 0.75 ABL1 (0.49) MEN1KMT2AALDH1A1ALOX15MAPK1
SCHEMBL3610888 0.75 ABL1 (0.54) MEN1KMT2AALDH1A1ALOX15MAPK1
SCHEMBL3597000 0.75 MEN1 (0.73) MEN1KMT2AALDH1A1ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MEN1 3257/4885KMT2A 4116/4885ATP4A 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.